deucravacitinib

Also known as BMS-986165 and Sotyktu.

Latest news on deucravacitinib

7 November 2026
Johnson & Johnson: ICOTYDE improves disease activity in biologic‑naïve psoriatic arthritis

Phase 3 ICONIC‑PsA 1: 58% ACR20 vs 41% placebo at Week 16 for oral IL‑23R blocker; responses increased by Week 24 and safety was consistent.

29 October 2026
Takeda reports FY2026 H1 results and upgrades outlook

Revenue +8.4% AER; core operating profit +11.2% AER; ORZEYFUL approved in US/Japan/China; MIMRYLO launched in US; zasocitinib accepted for FDA Priority Review; FY outlook raised for FX.

11 June 2026
Takeda's zasocitinib outperforms deucravacitinib in Phase 3 psoriasis head-to-head

Once-daily oral TYK2 inhibitor showed statistical superiority to deucravacitinib for PASI100 and key secondary endpoints, with >35% achieving complete skin clearance at week 16.